A new breed of pharma manufacturingOver the last few years the effect of Brexit’s political instability on our industry has been inescapable as Share XA new breed of pharma manufacturinghttps://pharmaphorum.com/r-d/views-analysis-r-d/a-new-breed-of-pharma-manufacturing/
Creating a successful and productive partnershipStrategic partnerships are a vital part of the healthcare industry, allowing companies to be greater than the sum Share XCreating a successful and productive partnershiphttps://pharmaphorum.com/spotlight/future-of-generics/creating-a-successful-and-productive-partnership/
The Falsified Medicines Directive – truly an opportunity for pharma?Telling the fake from the true is often a challenge, particularly in this era of ‘fake news’. But, Share XThe Falsified Medicines Directive – truly an opportunity for pharma?https://pharmaphorum.com/spotlight/future-of-generics/falsified-medicines-directive-opportunity-pharma/
EU steps closer to generics and biosimilars manufacturing waiverA change to European rules on drug manufacturing that could benefit makers of generics and biosimilars is edging Share XEU steps closer to generics and biosimilars manufacturing waiverhttps://pharmaphorum.com/news/eu-steps-closer-to-generics-and-biosimilars-manufacturing-waiver/
FDA publishes premarket guidance on combination productsThe FDA has published new premarket guidance on efficient development and review of combination products, which often combine Share XFDA publishes premarket guidance on combination productshttps://pharmaphorum.com/news/fda-publishes-premarket-guidance-on-combination-products/
